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Abstract
The pathophysiology of cystic fibrosis (CF) lung disease remains incompletely understood. New explanations for the
pathogenesis of CF lung disease may be discovered by studying the patterns of protein expression in cultured human nasal
epithelial cells (HNEC). To that aim, we compared the level of protein expressions in primary cultures of HNEC from nasal
polyps secondary to CF (CFNP, n = 4), primary nasal polyps (NP, n = 8) and control mucosa (CTRL, n = 4) using isobaric tag for
relative and absolute quantification (iTRAQ) labeling coupled with liquid chromatography (LC)-MS-MS. The analysis of the
data revealed 42 deregulated protein expressions in CFNP compared to NP and CTRL, suggesting that these alterations are
related to CF. Overall, AmiGo analysis highlighted six major pathways important for cell functions that seem to be impaired:
metabolism, G protein process, inflammation and oxidative stress response, protein folding, proteolysis and structural
proteins. Among them, glucose and fatty acid metabolic pathways could be impaired in CF with nine deregulated proteins.
Our proteomic study provides a reproducible set of differentially expressed proteins in airway epithelial cells from CF
patients and reveals many novel deregulated proteins that could lead to further studies aiming to clarify the involvement of
such proteins in CF pathophysiology.
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Introduction
Chronic inflammation, which represents one of the most serious
causes of morbidity/mortality in the world, is a severe complica-
tion common to both frequent and rare disorders. Among chronic
inflammatory disorders, cystic fibrosis (CF) is the most common
recessively inherited disease in the Western world. CF is caused by
mutations in the gene encoding the cystic fibrosis transmembrane
conductance regulator (CFTR) protein [1], which is expressed in
airway epithelial cells and acts as a chloride channel activated by
cyclic AMP. The most frequent mutation of CF alleles is F508del,
a deletion of phenylalanine in the intra-cytosolic nucleotide
binding domain 1 of CFTR.
Primary nasal polyposis, a common disorder of the upper
airways [2] which affects almost 4% of the population, is an
inflammatory disease of unknown etiology. Interestingly, CF is
often associated with nasal polyps [3] that constitute an accessible
model to study CF pathophysiology.
Global approaches may be useful to unmask abnormal cellular
pathways in complex chronic inflammatory diseases. A few
proteomic studies have been performed in CF with different
sample sources: sputum [4,5], bronchio-alveolar lavage fluid [6] or
serum [7]. Only three global proteomic studies have been
performed in airway epithelial cells which are one of the main
targets in CF: two in lung epithelial cell lines IB3-1 (i.e.
immortalized bronchial epithelial cell line isolated from a patient
homozygous for the F508del mutation) and C38 (i.e. IB3-1
‘‘corrected’’ by transfection with wild type CFTR) [8,9] and the
last one in cells obtained by nasal brushing (including blood,
inflammatory and epithelial cells) from CF patients [10]. To our
knowledge, no proteomic studies have been done on primary
cultures of pure airway epithelial cells from CF patients (i.e. not
contaminated with blood and/or inflammatory cells). This culture
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system allows epithelial cell differentiation at the air/liquid
interface and is useful to study chronic inflammation in airways
[11].
The effects of F508del CFTR are complex at the cellular level
and are known to alter many different functions [11–13]. Among
them, metabolism, G protein process, inflammation, oxidative
stress response, protein folding, proteolysis and structural proteins
are known to be abnormal but the proteins implicated in those
malfunctions are largely unknown.
The aim of the present study was to compare the levels of
protein expressions in primary cultures of human nasal epithelial
cells (HNEC) from control mucosa (CTRL), primary nasal polyps
(NP) and NP secondary to CF (CFNP). We chose differential
quantitative global proteomic analysis based on isobaric tag for
relative and absolute quantification (iTRAQ) labeling coupled
with liquid chromatography (LC)-MS-MS that permitted repro-
ducible protein quantification in the different patients evaluated in
this study. The iTRAQ method is based on the covalent labeling
of the amines from proteins with isobaric tags containing a
different distribution of heavy isotopes. The fragmentation of the
attached tag generates a low molecular mass reporter ion that can
be used to relatively quantify the peptides and the proteins from
which they originated.
The results provided new insights into the comprehension of
abnormal airway epithelial cell functions that might exist in CF
pathogenesis.
Materials and Methods
Subjects
In order to evaluate the differential protein expression related to
CF four patients with CFNP were randomly matched to four non-
CF patients affected by NP (CFNP vs. NP), and four other non-CF
patients with NP were matched to four CTRL patients without
nasal polyposis (NP vs. CTRL) (Figure 1).
All NP samples were collected from patients requiring surgery
for their nasal polyposis. Patients were requested to stop all
treatments at least one month before surgery except for CF
patients who were prepared for surgery by systemic antibiotics
adapted to nasal bacteriology. Four control mucosa from the
inferior turbinate were obtained from individuals who underwent
turbinectomy for snoring. All the patients did not mention any
allergic background and were negatively tested with skin prick
tests. All non-CF patients with NP presented typical primary nasal
polyposis and did not suffer from recurrent airway infections. In
order to avoid, as much as possible, heterozygous carriers of the
F508del mutation, nasal polyps occurring in a context of purulent
chronic sinusitis were not included [14]. All four CF patients were
homozygous for the F508del mutation. The CTRL and NP
patients were not genotyped for CF mutations. Characteristics of
the patients are given in Table 1. This protocol was approved by
the ethics committee of our institution (Comite´ de Protection des
Personnes-Ile-de-France IX CHU Henri Mondor). The partici-
pants provided their verbal consent to participate in the study and
their non opposistion to the use of their data. Parental consent was
obtained for minor subjects. The nasal mucosa collected for the
experiments were either nasal polyps or turbinates obtained during
ethmoidectomy or turbinectomy, respectively. All these samples
were surgical waste, usually discarded during surgery. Our
procedure is based on French law nu2004-800 of 6 August 2004
on Bioethics (‘‘loi relative a` la bioe´thique’’) which was codified in
the French Public Health Code (L. 1235-2 and L. 1245-2). The
surgeon recorded in the patient’s file the non-opposition for using
the discarded nasal mucosa.
Material
Reagents for mass spectrometry and protein
biochemistry experiments. dithiothreitol (DTT), pronase,
ethylenediamine tetra-acetic acid (EDTA), collagen IV, urea,
thio-urea, orthovanadate, glycerol, TRIS, iodoacetamide, NaCl,
detergents (CHAPS, sodium deoxychotate, Triton X100),
NH4CO3 and the Glu-fibrinopeptide were from Sigma-Aldrich
(Saint-Quentin Fallavier, France). Anti-proteases were from Roche
(Neuilly sur Seine, France). Bromophenol blue, SDS, acrylamide,
silver staining kit were from Biorad (Marnes la Coquette, France).
Trypsin for mass spectrometry was of highest grade purchased
from Promega (Charbonnieres-les-bains, France). Acetonitril
(ACN) and Tri-fluoro-acetic acid (TFA) were from Carlo Erba
(Val de Reuil, France), Alpha-Cyano-4-Hydroxycinnamic Acid
Figure 1. Workflow for the study. Two series of independent experiments were compared: (i) experiments 1 to 4 for proteins derived from HNEC
cultures obtained from 4 CF NP patients vs. 4 NP patients (non CF); (ii) experiments 5 to 8 for proteins derived from HNEC cultures obtained from 4 NP
patients (non CF) vs. 4 controls patients. Each couple of samples was matched randomly. For quantification of proteins, iTRAQ labeling coupled to LC-
MS/MS was performed (see methods for details).
doi:10.1371/journal.pone.0108671.g001
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(HCCA) from Laser Biolabs (Sophia-Antipolis, France). iTRAQ
reagents were from Applied Biosystems (Courtaboeuf, France)
Columns. C18 trap column (C18 pepmap100, 5 mm parti-
cles, 100 A˚ pores, 300 mm i.d., 5 mm length), and C18 analytical
column (C18 pepmap100, 3 mm particles, 15 cm length, 75 mm
inner diameter., 100 A˚ pores) were from Acclaim (Vandoeuvre,
France). The Ultimate3000 series HPLC and the Probot fraction
collector were purchased from Dionex (Voisins le Bretonneux,
France).
Primary cultures of HNEC
Nasal samples were transported to the laboratory in order to
perform primary cultures of HNEC as previously described [11].
Mucosa samples were rinsed in phosphate-buffered saline (PBS)
with dithiothreitol (DTT, 5 mM) and antibiotics (100 U/ml of
penicillin, 100 mg/ml of streptomycin, 2.5 mg/ml of amphotericin
B and 100 mg/ml of gentamicin) and then placed overnight at
4uC in a PBS-antibiotics solution containing 0.1% pronase. The
samples were incubated in DMEM/F12 with 5% fetal calf serum
(FCS) before centrifugation (800 g, 7 min). Cell pellets were then
suspended in 0.25% trypsin-EDTA solution for 3 min and
incubated in DMEM/F12-antibiotics with 10% FCS. Finally,
HNEC were plated on permeable polycarbonate supports at
16106 cells/cm2. All inserts had a diameter of 12-mm and were
coated with type IV collagen. HNEC were incubated at 37uC in
5% CO2. For the first 24 h, HNEC were incubated with 1 ml of
DMEM/F12-antibiotics with 2% Ultroser G outside the insert and
DMEM/F12-antibiotics with 10% FCS inside the insert. After
24 h, medium was removed inside the inserts in order to place the
cells at an air-liquid interface, and medium outside the inserts was
then changed daily. Transepithelial resistance and potential
difference were measured every three days using a microvoltmeter
(World Precision Instruments, Astonbury, UK). The primary
culture of HNEC, differentiated at the air-liquid interface,
provides functional cells closely resembling normal airway
epithelium within one week that maintain their differentiation
for at least four weeks [15]. We previously controlled that all
cultured cells are epithelial cells, with viability around 95% during
the first four weeks. For all experiments the cells were studied at
day 7 after seeding, corresponding to the establishment of cell
differentiation.
Protein preparation for proteomic experiments
Experiments for protein quantification were performed in
primary cultures of HNEC from CFNP, NP and CTRL. Cells
in Transwell filters were washed, scraped off the filters in ice-cold
PBS, and centrifuged (800 g, 10 min, 4uC). The pellet was
suspended in 100 ml/culture plate of lysis buffer, constituted of
0.5% w/v SDS, 50 mM Tris-HCl pH 7, before incubation at
95uC for 5 min. The total cellular proteins obtained were
supplemented by 250 ml/culture plate of dissolution buffer,
constituted of 8 M urea, 2.5 M thio-urea, 4% w/v CHAPS,
50 mM DTT, anti-protease 1X, 1 mM orthovanadate, and mixed
one h at room temperature. Labeling of proteins with iTRAQ
reagents, protein fractionation and digestion were performed
according to previously described protocols [16].
Table 1. Description of patients.
Patient Sex Age (years) Associated disease Cigarette smoke
CTRL
CTRL 5 M 32 None No
CTRL 6 F 24 None No
CTRL 7 M 28 None No
CTRL 8 M 20 None Yes
CFNP*
CFNP 1 M 21 None No
CFNP 2 F 15 None No
CFNP 3 M 22 None No
CFNP 4 F 25 None No
CFNP 5 F 19 None No
CFNP 6 M 21 None No
CFNP 7 M 17 None No
NP
NP 1 M 25 Samster’s disease No
NP 2 F 29 Aspirin intolerance Yes
NP 3 M 35 Asthma No
NP 4 F 34 Asthma No
NP 5 M 33 Samster’s disease No
NP 6 F 23 Asthma No
NP 7 M 37 Asthma No
NP 8 F 41 Samster’s disease No
*All CFNP patients are homozygous for the F508del CFTR mutation.
doi:10.1371/journal.pone.0108671.t001
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iTRAQ labeling
After protein preparation, 25 mg of each sample were precip-
itated overnight at 220uC using 100% acetone and dissolved in
20 ml of denaturing buffer containing 1 ml denaturant and 2 ml
reducing reagent (TCEP) as provided in the iTRAQ kit, followed
by vortexing and incubation at 60uC for 1 h. One ml of cysteine
blocking solution (iodoacetamide) was then added to each sample,
followed by incubation at room temperature for 30 min. iTRAQ
labeling was carried out by adding iTRAQ reagents 114, 115, 116
or 117 to either the NP, CF NP or CTRL samples followed by
incubation at room temperature for 2 h. For the NP/CFNP
experiments, iTRAQ reagent 114 was used for NP and the 116
was used for CFNP. For the NP/CTRL experiments: iTRAQ
reagent 115 was used for NP and the 117 was used for CTRL.
Subsequently, two samples/experiment (NP/CF NP or NP/
CTRL) were mixed by vortexing, pooled together and dried in a
Speedvac evaporator (Thermo Fisher Scientific, Courtaboeuf,
France).
Trypsin digestion
Samples were digested according to Bensalem et al [17] with
minor modifications. Briefly, prior to mass spectrometry analysis,
the dry iTRAQ sample pellet was dissolved in Laemmli buffer,
constituted of 10% glycerol, 0.05 M Tris-HCl (pH 6.8), 0.1%
SDS, 50 mM DTT, and 0.01% (w/v) bromophenol blue, then
supplemented by 1/5 H2O dilution. Dissolved proteins were
separated by electrophoresis (SDS-PAGE). Briefly, protein samples
were loaded onto 10% w/v polyacrylamide gels and run at 25 mA
for 2 to 3 h at room temperature. After electrophoresis, protein
visualization was carried out by silver staining compatible with
MS/MS analysis.
12 protein bands were excised from the SDS-PAGE gel and
prepared as follows: each gel piece was destained for 5 min with
200 ml of destaining buffer (silver staining kit). Before drying the
gel pieces in a Speedvac evaporator, they were washed with de-
ionised water (Millipore, Guyancourt, France) and shrunk in the
presence of Acetonitril for 15 min. The gel pieces were dried at
room temperature for 20 min and followed by digestion with
0.8 mg (4 U) of trypsin in 8 ml of 25 mM NH4/CO3, overnight at
37uC. The peptide mixture was extracted from the gel plug with
10 ml of a 50% ACN, 0.1% tri-fluoro-acetic acid solution and
dried in a Speedvac evaporator.
Nano-LC-MALDI-TOF-TOF
Nanochromatography protocol. Digested peptides were
suspended in water with 0.1% TFA and 10% acetonitrile,
separated with an Ultimate3000 series HPLC. Briefly: 10 mL of
eluate were injected and trapped using solvent A (0.1%
Figure 2. Distribution of the 186 common quantified proteins in CFNP (outer donut) and NP (inner donut) vs CTRL. Downregulated
proteins are highlighted in yellow, upregulated proteins are highlighted in red and stable proteins are highlighted in green according to the ratio
thresholds (R =CF NP/CTRL or NP/CTRL). 15 proteins are upregulated in NP compared to CTRL (inner donut) and 21 proteins are upregulated in CFNP
compared to CTRL (outer donut). Among them, 11 proteins are upregulated in both CFNP and NP. 20 proteins are downregulated in NP compared to
CTRL (inner donut) and 48 proteins are downregulated in CFNP compared to CTRL (outer donut). Among them, 16 proteins are downregulated in
both CFNP and NP. Finally, among the proteins deregulated in common between CFNP and NP, two are more regulated in CFNP and three are more
downregulated in CFNP. The 42 proteins of interest for CF pathophysiology are represented in intense red and intense yellow outside the outer
donut.
doi:10.1371/journal.pone.0108671.g002
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Trifuoroacetic acid, 2% ACN) at a 30 ml/min loading flow for
3 min in a C18 trap column. The microvalve then oriented the
elution to back flow (300 nl/min) the peptides toward the
analytical column with a gradient rising from 7% solvent B
(80% acetonitrile, 20% solvent A) at microvalve switch to 16% in
7 min, from 16% to 32% in 20 min and from 32% to 50% in
7 min. Fractions were spotted on-line on a MALDI target using a
Probot fraction collector. Spotted fractions were mixed 1:4 with
2 mg/ml of HCCA in 70% ACN 0.1% TFA and Glu
fibrinopeptide at 30 fmoles/spot. 96 fractions were collected and
analysed using a 4800 MALDI TOF/TOF analyser (ABI, Lyon -
Rhoˆne-Alpes, France).
MS mode. Spectra acquisition and processing were per-
formed using the 4000 series explorer software (ABI) version
3.5.28193 build 1011 in positive reflectron mode at fixed LASER
fluency with low mass gate and delayed extraction. External plate
calibration was performed using 4 calibration points spotted
throughout the plate, additional internal calibration was per-
formed using the Glu-fibrinopeptide (M/Z = 1570.677) allowing a
mass accuracy of few ppm. For each fraction, steps of 50 spectra in
the range of 700 to 4000 Da were acquired at a 200 Hz LASER
shot frequency. 500 spectra per sample were summed and
processed to obtain monoisotopic values from isotopes clusters
with a raw spectra s/n ratio of 20.
MS/MS mode. In each MS spectrum, the 8 most abundant
peaks were selected for fragmentation starting with the least
abundant. A cut off was applied at a minimum s/n of 20.
Neighboring precursors within resolution of 200 were excluded.
1000 MS/MS spectra per precursor were summed by increments
of 50. Processing included baseline subtraction and Stavitsky
Golay smoothing with 15 points across peak and a polynomial
order of 4. Peaklists reflect monoisotopic values from isotope
clusters with a s/n ratio of minimum 22.
Peak list and quantification analysis. Generated MS/MS
peaklists were subsequently submitted to an in-house Mascot
version 2.2 search engine (Matrix science). The Swiss-Prot 55.5
release Swiss-Prot 20080610 (389046 sequences; 139778124
residues) release database was used with the Homo sapiens
species. Parent and fragment mass tolerances were respectively set
to 50 ppm and 0.3 Da. Variable modification, oxidation (M),
iTRAQ 4plex (Y) and fixed modification, iTRAQ 4plex (N-term),
iTRAQ 4plex (K), carbamidomethylation (C) were allowed.
Trypsin digestion and possibility of one missed cleavage were
selected. A filter was applied to the search in order to reduce false
positives and matching redundancies of the same peptide in
several hits. All matches above 1% risks of random matching were
eliminated (p,0.01). The probability score calculated by the
software was used as a primary criterion for correct identification.
For Mascot scores slightly above the threshold of p value,
measurement errors were carefully watched to detect possible
false positives that usually give random mass measurement errors,
while relevant identifications give constant measurement errors.
Molecular weights from experimental and Mascot results were also
compared. Whenever the result was ambiguous, the spectra either
in MS or MS/MS were manually checked for proper matching
and the result was accordingly rejected or accepted.
Figure 3. Comparison of differentially expressed proteins in CFNP compared to NP and CTRL. On the left, we report the ratios of 42
proteins significantly modulated in CFNP/CTRL vs NP/CTRL patients. On the right, we report proteins that are modulated in both CFNP/CTRL and NP/
CTRL patients. To obtain the CFNP/CTRL ratios, relative protein expressions ratios from CF NP/NP were normalized to the average of the ratios
obtained in NP vs CTRL (CF NP/CTRL=CFNP/NP6NP/CTRL).
doi:10.1371/journal.pone.0108671.g003
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Statistical analysis for proteomic experiments
For the quantification, the protein ratio type was the ‘weighted’
geometric mean, only ‘bold face ratios’ were considered (signifi-
cantly different from 1 at a 95% confidence level), outlier removal
was ‘automatic’ (Dixon’s method and Rosner’s method), the
minimum number of peptides was two and at least two peptides
were required to be the top ranking peptide matches (‘bold and
red type faces’). Selective criteria were adopted to obtain a
consistently quantified set of proteins: (i) the intensity ratio must be
calculated with at least two unique quantified peptides and (ii) the
protein must be quantified in at least 3/4 experiments. Differences
between expression of proteins in CFNP vs NP were evaluated by
Mann-Whitney test p-value,0.05 (mostly confirmed by Student
test with Aspin-Welch correction, p-value,0.05) (Table S1).
Proteins were therefore considered up/down-regulated if the
average of the ratio of the protein expression were .1.37 and ,
Figure 4. Western blot analysis of seven differentially expressed proteins. The Western blots from the 4 NP patients and the 4 CFNP
patients used for proteomic experiments are shown with their respective loading controls. A: Each protein is analyzed in three technical replicates.
For normalization, the acrylamide gels were stained with Coomassie blue (total migrated protein detection) just after electro-transfer and scanned
using the Odyssey LI-COR. Using the Odyssey software, protein intensity values were normalized with their corresponding loading control intensity
values. B: Box plots of the intensity calculated with the Odyssey software, *p,0.01, Mann and Whitney test. (a.u.: arbitrary units). We report Maximum
(max), minimum (min), first quartile (Q1), third quartile (Q3).
doi:10.1371/journal.pone.0108671.g004
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0.73. To determine this threshold, we calculated the standard
deviations of the protein ratios for each experiment, we
normalized the Gaussian distributions and we calculated the
average threshold to select the proteins upregulated (last 20% on
the right of the Gaussian) and the more downregulated under-
expressed (first 20% on the left of the Gaussian). These thresholds
are in agreement with other studies using iTRAQ labeling [18].
Finally, the reliably quantified protein data set for both series of
experiments were analysed using the AmiGO toolbox kit (http://
amigo.geneontology.org/cgi-bin/amigo/term_enrichment and
Cytoscape software).
SDS PAGE and Western blot
All Western blot analyses were performed according to
previously described protocols [11]. Analysis of protein expression
in HNEC was performed using antibodies directed against human
STIP1, TERA, EZRI, ANXA1, 1433S, KPYM and HSPB1. All
the used primary and secondary antibodies are listed in the
Figure 5. Western blot analysis of ANXA1, STIP1, TERA, KPYM, HSPB1, EZRIN and 1433S in primary cultures of human nasal
epithelial cells (HNEC) from NP (n=4) and CFNP (n=4). A: Each protein was analyzed in three technical replicates. For normalization, the
acrylamide gels were stained with Coomassie blue (total migrated protein detection) just after electro-transfer and scanned using the Odyssey LI-
COR. Using the Odyssey software, protein intensity values were normalized with their corresponding loading control intensity values. B: Box plots of
the intensity calculated with the Odyssey software, *p,0.01, Mann and Whitney test. (a.u.: arbitrary units). We report Maximum (max), minimum
(min), first quartile (Q1), third quartile (Q3).
doi:10.1371/journal.pone.0108671.g005
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supplemental data with all the details including stock concentra-
tions, used dilutions, manufacturer details and specificity (Table
S2). For Western blots realized from NP 1, 2, 3, 4 and CFNP 3, 5,
6, 7, experiments were performed on four patients per category
and in triplicate. Mann and Whitney test was used for comparison
of data series and P values#0.01 were considered statistically
significant. Data are expressed with Box plots including median,
maximum and minimum values and first and third quartiles.
SDS PAGE. Proteins were prepared as follows: first, HNEC
from CF NP, NP and CTRL in Transwell filters were washed
twice, scraped off the filters in ice-cold PBS, and centrifuged at
800 g for 10 min at 4uC. Second, the pellet was re-suspended in
500 ml of RIPA lysis buffer constituted of 150 mM NaCl, 50 mM
Tris-HCl (pH 7.6), 1% v/v Triton X-100, 0.1% w/v SDS, 1% w/
v sodium deoxychotate and antiprotease 1X, and kept on ice for
30 min under agitation. Third, the cell lysates were then
centrifuged (20 000 g, 15 min) at 4uC. Finally, samples of the
supernatants (20 mg protein in 1 volume Laemmli buffer
containing 10% glycerol, 0.05 M Tris-HCl (pH 6.8), 0.1% SDS,
50 mM DTT, and 0.01% (w/v) bromophenol blue) were loaded
onto 10% w/v polyacrylamide gels and run at 25 mA for 2 to 3 h
at room temperature and electrically transferred at 200 mA for
90 min to nitrocellulose membranes.
Western blot analysis. The proteins of interest were
detected using appropriate first and secondary antibodies all used
at 1:15000 dilution. The infra-red signal was obtained by scanning
with the Odyssey LI-COR (Techsciences, Cergy Saint Christophe,
France). Quantification of protein levels was obtained using the
Odyssey LI-COR software. For normalization, the acrylamide gels
were stained with Coomassie blue (total migrated protein
detection) just after electro-transfer [19] and scanned using the
Odyssey LI-COR.
Results
Comparison of protein expression patterns in CFNP, NP
and CTRL
186 proteins were quantified across eight patients in both sets of
experiments (CFNP vs. NP and NP vs. CTRL). The distribution of
modulated proteins was different in CF and NP: CFNP presented
a higher proportion of deregulated proteins (24 upregulated and
65 downregulated) than NP patients (15 upregulated and 20
downregulated). In order to identify the proteins that were
specifically deregulated in CFNP patients, we selected proteins
that are significantly modulated in CFNP patients compared to NP
patients. 8 proteins were upregulated in CFNP, but stable in NP
patients, 29 were downregulated in CFNP but stable in NP, 3
proteins were significantly more downregulated and 2 proteins
more upregulated in CFNP than in NP (Figure 2). In addition, 11
proteins were equally upregulated and 16 proteins were equally
downregulated in both CFNP and NP. The expression ratios of
the modulated proteins are presented in Figure 3 (Table S1 for full
details). Seven of these 42 differential proteins (TERA, EZRIN,
STIP1, KPYM, ANXA1, HSP27 and 1433S) were analyzed by
Figure 6. Expression pattern of the 42 differential proteins of interest in CF. The 42 differential proteins are displayed in seven different
classes related to their functions (according to the AmiGO toolbox kit). Left graph: metabolism (class 1), G protein process (class 2), inflammation and
oxidative stress (class 3); right graph): protein folding (class 4), proteolysis (class 5), structural protein (class 6), other (class 7). The green circle
represent the absolute stable ratio value (R = 1) and the green area represent the ratio thresholds (0.73#R#1.37) (R =CFNP/CTRL or NP/CTRL). Scale
graduations for R are 0.2 and 0.5 for left and right graph, respectively. The CFNP/CTRL ratio values of the differential proteins are represented by
yellow dots (downregulated in CFNP) and red dots (upregulated in CFNP); the NP/CTRL ratio values are represented by yellow squares
(downregulated in NP), red squares (upregulated in NP), and green squares (stable in NP). For the proteins in bold, the modulation was confirmed by
Western blot. Protein names are from Swissprot, ratio values and p values are available in supplemental material (Table S1).
doi:10.1371/journal.pone.0108671.g006
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Western blot on patients CFNP1, 2, 3, 4 and NP1, 2, 3, 4
(Figure 4). To extend our validation we repeated the Western blot
analysis, on three new additional CFNP patients (CFNP5, 6, 7).
Furthermore, technical reproducibility of Western blot analysis,
was also assessed by performing three technical replicates for the
seven above-mentioned proteins derived from NP1, 2, 3, 4 and
CFNP3, 5, 6, 7 (Figure 5A). The statistical analysis of Western blot
results confirmed fully the differential expressions observed in the
proteomic quantification data (Figure 5B).
Functional distribution of the differential proteins in
CFNP/CTRL
To further investigate the altered molecular mechanisms in CF
epithelial cells, the differential proteins were analyzed using the
AmiGO toolkit which allows highlighting the most represented
classes of proteins in a given set. For the retained 42 proteins
specifically modulated in CFNP, the AmiGO analysis revealed six
major classes of proteins important for cell functions: metabolism,
G protein process, inflammation and oxidative stress response,
protein folding, proteolysis and structural proteins (Figure 6).
Metabolism (class 1). Thirteen proteins implicated in
metabolism were downregulated specifically in CFNP. Among
them, seven proteins implicated in glycolysis related metabolism
(KPYM, G6PD, ODPA, G6PI, PGAM1, TALDO and TKT)
were found downregulated in CFNP and stable in NP suggesting
metabolism abnormalities related to CF. Four of these proteins are
directly implicated in the canonical glycolytic pathway, pyruvate
kinase (KPYM), glucose phosphate isomerase (G6PI), glucose
phosphate dehydrogenase 1 (G6PD) and pyruvate dehydrogenase
(ODPA). Three other proteins, phosphoglycerate mutase 1
(PGAM1), transketolase (TKT) and transaldolase (TALDO), are
implicated in the interconnection between glycolysis and the
pentose pathway (Figure 7). In addition, four proteins implicated
in amino-acid metabolism, arginosuccinate synthase (ASSY),
glutamine synthetase (GLNA), asparaginyl-tRNA synthetase
(SYNC), oxoglutarate dehydrogenase (ODO1), and two proteins
implicated in fatty acid metabolism, medium-chain specific acyl-
CoA dehydrogenase (ACADM) and fatty acid synthase, (FAS)
were also significantly downregulated in CFNP compared to NP
and CTRL.
G protein process (class 2). Three proteins implicated in
these pathways were significantly downregulated in CFNP
compared to NP and CTRL, Rho GDP-dissociation inhibitor 1
(GDIR1), 14-3-3 proteins sigma and beta (1433S, 1433B),
suggesting possible abnormalities in the ligand/receptor respon-
siveness in CF.
Inflammation and oxidative stress response (class
3). Six proteins implicated in enzymatic antioxidant response
and inflammation were found to be downregulated in CFNP
compared to NP and CTRL. Among them, three inflammation-
related proteins, arachidonate 15-lipoxygenase (LOX15), annexin
Figure 7. Diagram of the glycolysis/pentose pathway indicating the 7 downregulated proteins in CFNP.
doi:10.1371/journal.pone.0108671.g007
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A1 (ANXA1) and heat shock protein beta 1 (HSPB1) were stable
in NP compared to control suggesting a CF specificity. Three
proteins related to oxidative stress, the peroxiredoxins 1, 2 and 6,
(PRDX1, 2 and 6), were downregulated in CFNP and NP
compared to CTRL. However, these downregulations in CFNP
were significantly lower compared to NP suggesting that these
anomalies are present in both nasal polyposis but they are more
severe in CF.
Protein folding (class 4). Four protein folding-related
proteins were found significantly downregulated in CFNP whilst
stable in NP. Interestingly, these proteins, heat shock protein 90-
alpha and cognate 71 (HS90A, HSP7C), transitional endoplasmic
reticulum ATPase (TERA), stress-induced-phosphoprotein 1
(STIP1), are known to participate in proper folding and
degradation of CFTR [20–22]. In addition, two proteins related
to protein folding in endoplasmic reticulum were upregulated in
CFNP with significant differences with NP, glucose-regulated
protein 78 (GRP78) and endoplasmin (ENPL). These proteins are
known to be upregulated in the unfolded protein response (UPR)
[23].
Proteolysis (class 5). Three proteins implicated in proteol-
ysis were upregulated, serpin B3 (SPB3), cathepsin B (CATB) and
dipeptidyl peptidase 2 (DPP2) and one downregulated, serpin B1
(ILEU), in CFNP and stable in NP suggesting proteolysis
abnormalities related to CF.
Structural proteins (class 6). Focusing on the cytoskeleton,
we observed four proteins upregulated, keratins 6A, 14, 17 and 5
(K2C6A, K1C14, K1C17, K2C5) and three downregulated, ezrin
(EZRI), tubulins alpha 1A and 4A (TBA1A and TBA4A) in CFNP
and stable in NP compared to CTRL suggesting a cytoskeleton
reshuffle in CF.
Other (class 7). The HLA class II-associated protein I (SET)
was downregulated in CF and is implicated in MAP kinase
signaling since it regulates ERK1/2 phosphorylation [24]. We
found an upregulation of the lysosome-associated membrane
protein 1 (LAMP1), a well-known lysosomal membrane marker
[25] suggesting an increased degradation activity in CF. Finally,
the major vault protein (MVP) was downregulated in CF and is
implicated in the bacterial resistance of lung epithelial cells [26].
Discussion
In this study we found 42 proteins significantly and specifically
modulated in CFNP patients. For seven of these proteins the
results were validated by Western blot in the eight patients
analysed by proteomics and in three additional CF patients. Our
data are also supported by previously published studies by us
[11,13,27] and by others [9,10] showing deregulation of ANXA1
(in CFTR2/2 mouse), of GRP78 for UPR activation (in both
CFNP and NP), of PRDX6, PRDX2, CATB, HSPB1, PDIA3,
ANXA1, VIME and EZRI (in CF cells). Importantly, we found
many novel differentially expressed proteins in CF NP that could
be of importance in CF pathophysiology.
Several proteins involved in CFTR synthesis/degradation were
found to be dowregulated in CF (HSP7C, HS90A, STIP1, TERA
and LAMP1), supporting previous observations of alteration of
folding and degradation pathways in CF [20,21]. HSP7C, HS90A
and STIP1 form a protein complex that assists correct CFTR
protein folding and participates in the degradation of misfolded
F508del CFTR by promoting ubiquitination [20,21,28]. In
addition, TERA plays an essential role in endoplasmic reticu-
lum-associated degradation [29] and is known to be involved in
the ER-associated degradation of CFTR [22]. Of note, TERA,
HSP7C and HS90A are present in the network of the CFTR
physical interaction proteins (Figure 8). These downregulations
observed in CF are surprising since F508del CFTR is mostly
retained in ER for degradation and remain to be investigated. In
addition, we observed an upregulation of a lysosomal membrane
marker, LAMP1 [25], perhaps related to a raised turnover of the
rescued F508del CFTR by the lysosomal pathway [30]. Altogeth-
er, these data may suggest a diminished folding-control/ER-
degradation of F508del CFTR associated with a rise in lysosomal-
mediated turnover, suggesting that F508del CFTR may be
preferentially degraded by the lysosomal pathway in our model.
Several proteins involved in inflammation and oxidative stress
were found to be deregulated in CF (PRDX1, 2 and 3, HSPB1,
LOX15, ANXA1 and MVP), supporting previous studies
[13,31,32]. PRDX1, 2 and 6 are implicated in enzymatic
antioxidant defenses and we have previously shown a downreg-
ulation of PRDX6 under oxidative challenge in CFTR2/2 mice
lungs [13]. In another study, PRDX6 has also been found to be
downregulated in HNEC of CF patients [10]. Another protein
linked to oxidative stress, HSPB1 is able to raise intracellular
glutathione levels [33] and activate ROS detoxification enzymes
such as the peroxiredoxins mentioned above [34]. The decreased
expression of these proteins in CFNP may result in lower
protection against oxidative stress suggesting a susceptibility to
oxidative damage in CF. LOX15 produces 15-hydroxyeicosate-
traenoic acid (15-HPETE), an inhibitor of inflammatory mediators
by promoting TNF mRNA decay [35]. ANXA1 is also known to
have anti-inflammatory properties [36]. The downregulation of
these two proteins participates in inflammation in CF by
deregulating the eicosanoid-related pathway. Interestingly, MVP
is known to participate in the resistance of airway cells to bacteria
and may participate in the well-known lower resistance of CF
patients to Pseudomonas aeruginosa infection [26].
Eight proteins belonging to the glucose and fatty acid metabolic
pathways were found to be deregulated in CF (KPYM, G6PI,
G6PD, ODPA, PGAM1, TALDO, TKT and ACADM). KPYM,
G6PI, G6PD, ODPA, PGAM1, TALDO and TKT are directly
implicated in the glycolysis/pentose pathway leading to NADPH
and acyl-CoA production (Figure 7). Interestingly, a recent
metabolomic study showed a diminished amount of glycolysis-
related metabolites in CF cells (i.e. glucose, glucose-6-phosphate,
fructose-6-phosphate) and concluded that glycolysis could be
suppressed in CF [12]. However, a recent study showed
upregulations of KPYM in IB3-1 cells compared to C38 cells,
concluding that glycolysis could be increased in CF [8]. This
discrepancy could be related to the differences between primary
cells and transfected cellular lineages. ACADM is the medium
chain of acyl-CoA dehydrogenase that is a key enzyme of fatty acid
beta-oxidation leading to acyl-CoA production. The protein
expression and activity of all these metabolic enzymes have never
been directly investigated in CF. Altogether, our data show that
the two major pathways leading to the production of NADPH and
acetyl-CoA seem to be altered in CF and could further aggravate
oxidative stress conditions.
Deregulation of proteases (SPB3 and CATB) and of a protease
inhibitor (ILEU) may participate in lung fibrosis frequently
observed in CF. SPB3, ILEU and CATB are important
inflammation modulators. SPB3 and CATB (upregulated in this
study) have been shown to promote lung, intestinal and liver
fibrosis, respectively, in mouse models [37,38]. Furthermore,
ILEU (downregulated in this study) is a leukocyte elastase inhibitor
that prevents lung fibrosis in mice [39]. These anomalies, detected
by us in upper airway epithelial cells, may represent at the cellular
level the molecular anomalies that could lead to lung fibrosis. In
addition, the upregulation of cytoplasmic structural proteins in CF
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(K2C5, K1C14, K2C6A and K1C17) and the downregulation of
TBA1A, TBA4A and EZRI, known to interact with CFTR by
anchoring it to the tubulin cytoskeleton [40,41], suggest a possible
intracellular remodeling of airway epithelial cells that could be
related to trafficking and/or stabilization processes. All together,
these results suggest a possible remodeling at the intra and extra
cellular levels.
G protein related pathways were found to be altered in CF,
suggesting numerous dysfunctions in CF cells. Three proteins
related to G protein signaling (GDIR1, 1433B and 1433S) and one
protein related to MAP kinase signaling (SET) (all downregulated)
are multifunctional proteins that regulate most of the major
cellular functions including proliferation, apoptosis, inflammatory
response, epithelial cell polarization and secretory processes [42].
Those downregulations could be related to some or many
alterations described above.
Finally, based on the Biogrid interaction database (http://
thebiogrid.org), we built the CFTR protein interaction network by
taking into account only proteins that directly interact with one
another, at first and second degrees. This network is composed of
198 proteins selected according to experimental criteria for direct
protein-protein interactions (surface plasmon resonance (SPR),
pull-down and FRET experiments). To this bibliographic network
we have added proteins identified in our laboratory using SPR and
DNA ligation assays [43]. It is of interest to note that 16 of the 186
quantified proteins in the present study could be mapped on our
handcurated CFTR physical network (Figure 8). Remarkably, 9
proteins out of these 16 were deregulated in CF patients (8 down
and 1 up), while only 4 of the 16 proteins were downregulated (3)
or upregulated (1) in NP patients (Figure 8). Those differentially
expressed proteins are cytoskeleton or chaperon proteins that are
all implicated in the folding, stability or degradation of CFTR. We
suggest that some of the deregulated proteins in CF patients may
be related to the perturbation of the CFTR/F508delCFTR
physical network.
Overall, our proteomic study provides a reproducible set of
differentially expressed proteins in airway epithelial cells from CF
patients. While some of our findings correlate with previous
studies, we have identified many novel differentially expressed
proteins that have not been previously studied in CF pathophys-
iology.
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Figure 8. Quantified proteins present in the CFTR physical network. Proteomics quantitative analysis allowed us to reproducibly quantify
186 proteins. Of those, 16 could be mapped on a hand curated CFTR physical network based on the Biogrid interaction database (http://thebiogrid.
org).This network is composed of 198 proteins selected according to experimental criteria for direct protein-protein interactions (surface plasmon
resonance (SPR), pull-down and FRET experiments). To this bibliographic network, we have added proteins identified in our laboratory using SPR and
DNA ligation assays. We built the CFTR protein interaction network by taking into account only proteins that directly interact with one another, at first
and second degrees. In the graph, we represent the 16 proteins with a color code corresponding to their expression status in CF (A) and NP (B)
compared to CTRL: upregulated (red), downregulated (yellow), stable (green). The network is completed by a minimal number of connecting proteins
of the CFTR network (white) that could not be identified or quantified by MS/MS. Proteins that are up or downregulated in both CFNP and NP are
marked by a grey star.
doi:10.1371/journal.pone.0108671.g008
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